Literature DB >> 21040917

Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population.

Qin Cui1, Xianxia Ju, Tao Yang, Mei Zhang, Wei Tang, Qi Chen, Yong Hu, Joseph V Haas, Jason S Troutt, Richard T Pickard, Ryan Darling, Robert J Konrad, Hongwen Zhou, Guoqing Cao.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor (LDLR) degradation. Gain-of-function and loss-of-function mutations within PCSK9 gene lead to hypercholesterolemia or hypocholesterolemia respectively. Studies in the U.S. and Canada reported a correlation between multiple metabolic factors and circulating PCSK9 concentrations. However, there is no data available on circulating PCSK9 levels in Chinese. A sandwich ELISA assay was applied to measure serum PCSK9 levels in a Chinese population of 2719 adults from Nanjing district, China, which represents a large and uniform ethnic population of Han Chinese. Serum PCSK9 levels ranged from 12.85 to 222.50 ng/ml with a mean concentration of 69.35 ng/ml in this population. Serum PCSK9 levels were slightly higher in women than in men. Compared to premenopausal women, postmenopausal women had significantly higher PCSK9 levels. Serum PCSK9 levels were correlated with multiple metabolic variables including age, BMI, total cholesterol, LDL cholesterol, triglycerides, fasting blood glucose, systolic blood pressure (SP) and diastolic blood pressure (DP) in this population. After stepwise regression analysis, there was a significant positive association between serum PCSK9 levels and total cholesterol, triglycerides and SP in men. In women, there was a positive correlation between PCSK9 levels and total cholesterol, age and DP. Our study indicates that the serum PCSK9 level may be a biomarker of metabolic status and cardiovascular disease.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21040917     DOI: 10.1016/j.atherosclerosis.2010.09.027

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  37 in total

1.  Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people.

Authors:  Shelby Sullivan; Elisa Fabbrini; Jay D Horton; Kevin Korenblat; Bruce W Patterson; Samuel Klein
Journal:  Transl Res       Date:  2011-07-19       Impact factor: 7.012

Review 2.  Lipid lowering with PCSK9 inhibitors.

Authors:  Razvan T Dadu; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

3.  Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.

Authors:  Jean-Philippe Drouin-Chartier; André J Tremblay; Jean-Charles Hogue; Valéry Lemelin; Benoît Lamarche; Patrick Couture
Journal:  J Lipid Res       Date:  2018-06-26       Impact factor: 5.922

Review 4.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

5.  Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.

Authors:  Amy E Levenson; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; R Paul Wadwa; Sudha B Biddinger
Journal:  Pediatr Diabetes       Date:  2017-01-17       Impact factor: 4.866

6.  Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.

Authors:  S-H Yang; S Li; Y Zhang; R-X Xu; C-G Zhu; Y-L Guo; N-Q Wu; P Qing; Y Gao; C-J Cui; Q Dong; J Sun; J-J Li
Journal:  J Endocrinol Invest       Date:  2016-02-19       Impact factor: 4.256

7.  Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects.

Authors:  Edem Nuglozeh; Mohammad Feroze Fazaludeen; Nabil Hasona; Tarja Malm; Luisito B Mayor; Awdah Al-Hazmi; Ibraheem Ashankyty
Journal:  Indian J Clin Biochem       Date:  2018-07-30

8.  Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.

Authors:  Moumita Ghosh; Cecilia Gälman; Mats Rudling; Bo Angelin
Journal:  J Lipid Res       Date:  2014-12-22       Impact factor: 5.922

9.  Isolation and characterization of the circulating truncated form of PCSK9.

Authors:  Bomie Han; Patrick I Eacho; Michael D Knierman; Jason S Troutt; Robert J Konrad; Xiaohong Yu; Krista M Schroeder
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

10.  Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives.

Authors:  Sheng-Hua Yang; Ying Du; Sha Li; Yan Zhang; Rui-Xia Xu; Cheng-Gang Zhu; Yuan-Lin Guo; Na-Qiong Wu; Qian Dong; Jing Sun; Jian-Jun Li
Journal:  Hypertens Res       Date:  2016-04-14       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.